Testing a new drug for lupus and related lung disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 55 years old if healthy, or 18 to 65 if you have lupus or lung disease.
- You must weigh at least 99 pounds (45 kilograms).
- Your body mass index (BMI) must be between 18 and 32.
- If you have lupus, you need a confirmed diagnosis using standard criteria.
- If you have lung disease related to connective tissue disease, you need a confirmed diagnosis and be on stable treatment.
- You must not have certain infections (like tuberculosis, hepatitis B or C, or HIV) or certain other health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.